Metabolic studies of breast cancer (review)
- Authors: Valembakhov I.S.1, Slynko N.M.2, Gulyaeva L.F.1,3, Kushlinskii N.E.4,5
-
Affiliations:
- Federal State Budgetary Institution "Federal Research Center for Fundamental and Translational Medicine"
- Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
- Novosibirsk State University
- Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» of the Russian Ministry of Health of Russia
- Federal State Budgetary Educational Institution of Higher Education Russian University of Medicine
- Issue: Vol 28, No 1 (2025)
- Pages: 48-55
- Section: Medical chemistry
- URL: https://ogarev-online.ru/1560-9596/article/view/278996
- DOI: https://doi.org/10.29296/25877313-2025-01-06
- ID: 278996
Cite item
Abstract
Metabolomics is a new approach in modern biomedical science, the purpose of which is to study unique chemicals specific to the processes occurring in living cells. Due to the continuous development of advanced analytical methods and bioinformatics, metabolomics is widely used as a new, holistic, diagnostic tool in clinical and biomedical research. Metabolic reprogramming is a hallmark of cancer. Studies have shown that in transformed cells, including the mammary gland, there are profound metabolic changes aimed at survival. The detection of oncometabolites is one of the important problems of modern science today, as it allows understanding the metabolic pathways of the transformed cell, which is important both for diagnosis and the search for new therapeutic targets. In connection with the development of new chemical technologies, it became possible to determine the level of steroids and their metabolites, as well as fatty acids in the tumor. One such method, along with NMR spectrometry and liquid chromatography, in conjunction with mass spectrometry (LC-MS), is gas chromatography with GC-MS mass spectrometry. Enormous progress in the application of these modern analytical methods allows for a deeper and more accurate description of metabolic processes.
This review article discusses some of the current and current hurdles in cancer metabolomics research. In addition, it reviews some of the most recent and exciting developments in metabolomics that may address some of these issues. The purpose of this article is to inform the oncometabolomics research community about the problems and possible solutions to these problems.
Full Text
##article.viewOnOriginalSite##About the authors
I. S. Valembakhov
Federal State Budgetary Institution "Federal Research Center for Fundamental and Translational Medicine"
Author for correspondence.
Email: i.valembakhov@g.nsu.ru
ORCID iD: 0009-0001-7727-7847
Junior Research Scientist
Russian Federation, Timakova street, 2, Novosibirsk, 630060N. M. Slynko
Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Email: nslynko@mail.ru
ORCID iD: 0009-0002-2512-4862
Ph.D. (Chem.), Senior Research Scientist
Russian Federation, pr. ak. Lavrentieva, 10, Novosibirsk, 630090L. F. Gulyaeva
Federal State Budgetary Institution "Federal Research Center for Fundamental and Translational Medicine"; Novosibirsk State University
Email: lfgulyaeva@gmail.com
ORCID iD: 0000-0001-5820-0513
Dr.Sc. (Biol.), Professor, Head of Laboratory; Head of Department of Clinical Biochemistry, IMPZ
Russian Federation, Timakova street, 2, Novosibirsk, 630060; Pirogova street, 1, Novosibirsk, 630090N. E. Kushlinskii
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» of the Russian Ministry of Health of Russia; Federal State Budgetary Educational Institution of Higher Education Russian University of Medicine
Email: biochimia@yandex.ru
ORCID iD: 0000-0002-3898-4127
Dr.Sc. (Med.), Professor, Academician of the Russian Academy of Sciences, Scientific Director of the Clinical Diagnostic Laboratory of the Consultative and Diagnostic Center; Head of Department of Clinical Biochemistry and Laboratory Diagnostics
Russian Federation, Kashirskoe highway, 24, Moscow, 115522; Dolgorukovskaya street, 4, Moscow, 127006References
- Yu X.H., Ren X.H., Liang X.H., Tang Y.L. Roles of fatty acid metabolism in tumourigenesis: Beyond providing nutrition (Review). Mol Med Rep. 2018; 6: 53075316. doi: 10.3390/ijms20030644.
- Zhenning J., Yang D. C., Shen H. Fatty acid metabolism and cancer. Adv. Exp. Med. Biol. 2021; 1280: 231241; https://doi.org/10.1007/978-3-030-51652-9_16.
- Lindon J.C., Nicholson J.K. Analytical technologies for me-tabonomics and metabolomics, and multi-omic information recovery. Trend Anal. Chem. 2008; 27: 194–204; https://doi.org/10.1016/j.trac.2007.08.009.
- Nagana Gowda G.A., Raftery D. NMR-Based Metabolomics. Adv. Exp. Med. Biol. 2021; 1280: 1937. doi: 10.1007/978-3-030-51652-9_2.
- Psychogios N., et al. The Human Serum Metabolome. PLoS ONE. 2011; 6: 123; https://doi.org/10.1371/journal.po-ne.0016957.
- Gika H.G., Theodoridis G.A., Plumb R.S., Wilson I.D. Current practice of liquid chromatography–mass spectrometry in metabolomics and metabonomics. J. Pharm. Biomed. Anal. 2014; 87: 1225; https://doi.org/10.1016/j.jpba.2013.06.032.
- Kind T., Wohlgemuth G., Lee D.Y., Lu Y., Palazoglu M., Shahbaz S., Fiehn O. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal. Chem. 2009; 81(24): 1003810048; https://doi.org/10.1021/ac9019522.
- Lenz E.M., Wilson I.D. Analytical strategies in metabonomics. J/ Proteome Res. 2007; 6(2): 443458; https://doi.org/10.1021/pr0605217.
- Naz S., Garcia A., Rusak M., Barbas C. Method development and validation for rat serum fingerprinting with CE–MS: application to ventilator-induced-lung-injury study. Anal Bioanal/ Chem. 2013; 405(14): 48494858; https://doi.org/10.1007/s00216-013-6882-5.
- Moraes E.P., Ruperez F.J., Plaza M., Herrero M., Barbas C. Metabolomic assessment with CE–MS of the nutraceutical effect of Cystoseira spp. extracts in an animal model. Electrophoresis. 2011; 32(15): 20552062; https://doi.org/10.1002/elps.201000546.
- Jobard E., Pontoizeau C., Blaise B.J., Bachelot T., Herr-mann B.E., Tre-dan O. A serum nuclear magnetic resonance-based metabolomic signature ofadvanced metastatic human breast cancer. Cancer Lett. 2014; 343(1): 3341; https://doi.org/10.1016/j.canlet.2013.09.011.
- Yoon H., Yoon D., Yun M., Choi J.S., Park V.Y., Kim E.K. et al. Metabolomics of breast cancer using high-resolution magic angle spinning magnetic resonance spectroscopy: correlations with 18F-FDG positron emission tomography-computed tomography, dynamic contrast-enhanced and diffusion-weighted imaging MRI. PLoS ONE. 2016; 11(7): 117; 10.1371/journal.pone.0159949' target='_blank'>https://doi: 10.1371/journal.pone.0159949.
- Vignoli A., Risi E., McCartney A., Migliaccio I., Moretti E., Malorni L., Luchinat C., Biganzoli L., Tenori L. Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. Int. J. Mol. Sci. 2021; 22(9): 126; https://doi: 10.3390/ijms22094687.
- Goto R., Nakamura Y., Takami T., Sanke T., Tozuka Z. Quantitative LC-MS/MS analysis of proteins involved in metastasis of breast cancer. PLoS One. 2015; 10(7): 1–14; https://doi.org/10.1371/journal.pone.0130760.
- Jasbi P., Wang D., Cheng S.L., Fei Q., Cui J.Y., Liu L., Wei Y., Raftery D., Gu H. Breast cancer detection using targeted plasma metabolomics. J Chromatogr. 2019; 1105: 2637; https://doi.org/10.1016/j.jchromb.2018.11.029.
- Jiao Z., Lu Z., Peng Y., Xu C., Lou Y., Wang G., Aa J., Zhang Y.J. A quantitative metabolomics assay targeting 14 intracellular metabolites associated with the methionine transsulfuration pathway using LC-MS/MS in breast cancer cells. Chromatogr. B Analyt. Technol. Biomed Life Sci. 2022; 1205: 12141233; https://doi: 10.1016/j.jchromb.2022.123314.
- Fiehn O. Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling. Curr Protoc Mol Biol. 2016; 114: 132; https://doi: 10.1002/0471142727.mb3004s114.
- Tan B., Zhang Y., Zhang T., He J., Luo X., Bian X., Wu J., Zou C., Wang Y., Fu L. Identifying potential serum biomarkers of breast cancer through targeted free fatty acid profiles screening based on a GC–MS platform. Biomed. Chromatography. 2020; 34: 110; https://doi.org/10.1002/bmc.4922.
- Beksac K., Reçber T., Çetin B., Alp O., Kaynaroğlu V., Kır S., Nemutlu E. GC-MS Based Metabolomics Analysis to Evaluate Short-Term Effect of Tumor Removal on Patients with Early-Stage Breast Cancer.J. Chromatogr Sci. 2022; https://bmac035. doi: 10.1093/chromsci/bmac035.
- Cao Y., Wang Q., Gao P., Dong J., Zhu Z., Fang Y., Fang Z., Sun X., Sun T. A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. Onco. Targets. Ther. 2016; 9: 13891398; https://doi.org/10.2147/OT-T.S95862.
- Jove M., Collado R., Quiles J.L., Ramírez-Tortosa M.-C., Sol J., Ruiz-Sanjuan M., Fernandez M., de la Torre Cabrera C., Ramírez-Tortosa C., Granados-Principal S., et al. A plasma metabolomic signature discloses human breast cancer. Oncotarget. 2017; 8: 19522–19533; https:// 10.18632/oncotar-get.14521.
- Cala M., Aldana J., Sánchez J., Guio J., Meesters R.J.W. Urinary metabolite and lipid alterations in Colombian Hispanic women with breast cancer: A pilot study. J. Pharm. Biomed. Anal. 2018; 152: 234–241; https://doi.org/10.1016/j.jp-ba.2018.02.009.
- Cavaco C., Pereira J.A.M., Taunk K., Taware R., Rapole S., Nagarajaram H., Câmara J.S. Screening of salivary volatiles for putative breast cancer discrimination: An exploratory study involving geographically distant populations. Anal. Bioanal. Chem. 2018; 410: 1–10; https://doi.org/10.1007/s00216-018-1103-x.
- Budczies J., Pfitzner B.M., Gyory B., Winzer K.-J., Radke C., Dietel M., Fiehn O., Denkert C. Glutamate enrichment as new diagnostic opportunity in breast cancer. Int. J. Cancer 2015; 136: 1619–1628. https://doi.org/ 10.1002/ijc.29152.
Supplementary files
